This Article Full Text Full Text (PDF) CME: Take the course for this article: Signal Events: Cell Signal Transduction and Its Inhibition in Cancer eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rowinsky, E. K. Search for Related Content PubMed PubMed Citation Articles by Rowinsky, E. K.

Signal Events: Cell Signal Transduction and Its Inhibition in Cancer

Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA

Correspondence: Eric K. Rowinsky, M.D., Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Road, 4th Floor Zeller Building, San Antonio, Texas 78229, USA. Telephone: 210-616-5945; Fax: 210-616-5865; e-mail: erowinsk{at}saci.org

Signal transduction refers to communication processes used by regulatory molecules to mediate the essential cell processes of growth, differentiation, and survival. Signal transduction elements interact through complex biochemically related networks. Aberrations in signal transduction elements can lead to increased proliferative potential, sustained angiogenesis, tissue invasion and metastasis, and apoptosis inhibition. Most human neoplasms have aberrant signal transduction elements. Several compounds that target aberrant signal transduction elements, such as those in the ErbB family of tyrosine kinase receptors and mammalian target of rapamycin, are in development. To date, commercially available signal-transduction-targeting compounds include trastuzumab, a monoclonal antibody against the ErbB-2 receptor for the treatment of metastatic breast cancer overexpressing the ErbB-2 (HER-2) receptor, and gefitinib, an inhibitor of the ErbB-1 receptor tyrosine kinase that recently received regulatory approval for the treatment of patients with non-small cell lung cancer. In contrast to traditional cytotoxic treatments, although signal transduction inhibitors are capable of inducing tumor regression, particularly in malignancies that are principally driven by specific target aberrations, preclinical and early clinical investigations suggest that their predominant beneficial effects are growth inhibitory in nature; therefore, new clinical trial designs and evaluation end points may be required to ultimately assess their value. Prospective profiling of patients and tumors to determine treatment response is also essential to the success of these clinical trials. However, responsiveness to these novel therapies is dependent on a multitude of factors that ultimately determine the robustness and quality of the downstream response.

Key Words. Signal transduction • Targeted cancer therapy • mTOR • ErbB family • Rapamycin

This article has been cited by other articles:

				V. Bertagnolo, M. Benedusi, F. Brugnoli, P. Lanuti, M. Marchisio, P. Querzoli, and S. Capitani Phospholipase C-{beta}2 promotes mitosis and migration of human breast cancer-derived cells Carcinogenesis, August 1, 2007; 28(8): 1638 - 1645. [Abstract] [Full Text] [PDF]

				C. Erlichman, M. Hidalgo, J. P. Boni, P. Martins, S. E. Quinn, C. Zacharchuk, P. Amorusi, A. A. Adjei, and E. K. Rowinsky Phase I Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors J. Clin. Oncol., May 20, 2006; 24(15): 2252 - 2260. [Abstract] [Full Text] [PDF]

				A. Bottomley, R. Gaafa, C. Manegold, S. Burgers, C. Coens, C. Legrand, M. Vincent, G. Giaccone, and J. Van Meerbeeck Short-Term Treatment-Related Symptoms and Quality of Life: Results From an International Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study J. Clin. Oncol., March 20, 2006; 24(9): 1435 - 1442. [Abstract] [Full Text] [PDF]

				P. Nieboer, C. Buijs, S. Rodenhuis, C. Seynaeve, L. V.A.M. Beex, E. van der Wall, D. J. Richel, M. A. Nooij, E. E. Voest, P. Hupperets, et al. Fatigue and Relating Factors in High-Risk Breast Cancer Patients Treated With Adjuvant Standard or High-Dose Chemotherapy: A Longitudinal Study J. Clin. Oncol., November 20, 2005; 23(33): 8296 - 8304. [Abstract] [Full Text] [PDF]

				P. Barrett-Lee, C. Bokemeyer, P. Gascon, J.W.R. Nortier, M. Schneider, D. Schrijvers, S. Van Belle, and for the Ecas Advisory Board and Participating Cent Management of Cancer-Related Anemia in Patients with Breast or Gynecologic Cancer: New Insights Based on Results from the European Cancer Anemia Survey Oncologist, October 1, 2005; 10(9): 743 - 757. [Abstract] [Full Text] [PDF]

				D. A. Ferguson, M. R. Muenster, Q. Zang, J. A. Spencer, J. J. Schageman, Y. Lian, H. R. Garner, R. B. Gaynor, J. W. Huff, A. Pertsemlidis, et al. Selective Identification of Secreted and Transmembrane Breast Cancer Markers using Escherichia coli Ampicillin Secretion Trap Cancer Res., September 15, 2005; 65(18): 8209 - 8217. [Abstract] [Full Text] [PDF]

				W. P. Tew, D. P. Kelsen, and D. H. Ilson Targeted Therapies for Esophageal Cancer Oncologist, September 1, 2005; 10(8): 590 - 601. [Abstract] [Full Text] [PDF]

				K. R McGaffin and S. A Chrysogelos Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1,25-dihydroxyvitamin D3 in breast cancer cells J. Mol. Endocrinol., August 1, 2005; 35(1): 117 - 133. [Abstract] [Full Text] [PDF]

				E. M. Perez, M. K. Hendricks, J. L. Beard, L. E. Murray-Kolb, A. Berg, M. Tomlinson, J. Irlam, W. Isaacs, T. Njengele, A. Sive, et al. Mother-Infant Interactions and Infant Development Are Altered by Maternal Iron Deficiency Anemia J. Nutr., April 1, 2005; 135(4): 850 - 855. [Abstract] [Full Text] [PDF]

				C. Osborne, P. Wilson, and D. Tripathy Oncogenes and Tumor Suppressor Genes in Breast Cancer: Potential Diagnostic and Therapeutic Applications Oncologist, July 1, 2004; 9(4): 361 - 377. [Abstract] [Full Text] [PDF]

				D. J. Slamon The Future of ErbB-1 and ErbB-2 Pathway Inhibition in Breast Cancer: Targeting Multiple Receptors Oncologist, June 3, 2004; 9(suppl_3): 1 - 3. [Full Text] [PDF]

				A. Zetser, F. Levy-Adam, V. Kaplan, S. Gingis-Velitski, Y. Bashenko, S. Schubert, M. Y. Flugelman, I. Vlodavsky, and N. Ilan Processing and activation of latent heparanase occurs in lysosomes J. Cell Sci., May 1, 2004; 117(11): 2249 - 2258. [Abstract] [Full Text] [PDF]

				D. Burtrum, Z. Zhu, D. Lu, D. M. Anderson, M. Prewett, D. S. Pereira, R. Bassi, R. Abdullah, A. T. Hooper, H. Koo, et al. A Fully Human Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Blocks Ligand-Dependent Signaling and Inhibits Human Tumor Growth in Vivo Cancer Res., December 15, 2003; 63(24): 8912 - 8921. [Abstract] [Full Text] [PDF]